Experimental Drug Study for Lupus Nephritis
Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
Recruiting
Phase 1
Interventional Study
Lupus Nephritis (LN)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 60
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 90 (estimated)
- Sponsor
- Regeneron Pharmaceuticals · Industry
Who this trial is looking for
This trial is looking for adults with Lupus Nephritis who have not responded to previous treatments. Participants will receive an experimental drug and be monitored for safety and side effects over time.
Are You a Good Fit for This Trial?
You may be able to join if
- I have been diagnosed with Systemic Lupus Erythematosus and Lupus Nephritis.
- I have refractory or relapsed disease.
You may not be able to join if
- I have a history of severe or unstable lupus-related brain issues.
- I have had active mixed connective tissue disease or systemic sclerosis in the last year.
- I have had catastrophic or severe antiphospholipid syndrome in the last year.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
This study is researching a particular group of experimental drugs administered for a short period in the treatment of participants with Lupus Nephritis (LN).
The main aim of the current study is to see how safe and tolerable the study drugs are in a long-term follow-up.
This is a main study, called an umbrella study, which includes several independent smaller sub-studies. Each of these smaller …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Key General Inclusion Criteria:
1. Diagnosis of Systemic Lupus Erythematosus (SLE) and LN, as described in the protocol
2. Participant must have refractory or relapsed disease, as described in the protocol
Key General Exclusion Criteria:
1. History of or active severe or unstable lupus-associated…
Contacts